Are stem cells drugs? The regulation of stem cell research and development

被引:15
作者
Rosen, Michael R.
机构
[1] Columbia Univ Coll Phys & Surg, Ctr Mol Therapeut, Dept Pharmacol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Ctr Mol Therapeut, Dept Pediat, New York, NY 10032 USA
关键词
cardiovascular diseases; cells; heart failure; myocardial infarction; trials;
D O I
10.1161/CIRCULATIONAHA.106.641670
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Stem cell research and its clinical application have become political, social, and medical lightning rods, polarizing opinion among members of the lay community and among medical/scientific professionals. A potpourri of opinion, near-anecdotal observation, and scientifically sound data has sown confusion in ways rarely seen in the medical arts and sciences. A major issue is regulation, with different aspects of stem cell research falling within the purview of different government agencies and local offices. An overarching clearinghouse to review the field and recommend policy is lacking. In the following pages, I touch on the societal framework for regulation, the known and potential risks and benefits of cardiovascular stem cell therapies, whether stem cells should be regulated as drugs or in analogy to drugs, and if there is to be regulation, then by whom. In so doing, I refer to the stem cell literature only as it relates to the discussion of regulation because this is not a review of stem cell research; it is an opinion regarding regulation.
引用
收藏
页码:1992 / 2000
页数:9
相关论文
共 59 条
[1]   Human mesenchymal stem cells modulate allogeneic immune cell responses [J].
Aggarwal, S ;
Pittenger, MF .
BLOOD, 2005, 105 (04) :1815-1822
[2]  
Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102
[3]  
[Anonymous], 2006, NEW YORKER
[4]  
Aries Philippe., 1974, Western Attitudes toward Death
[5]   Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction -: (TOPCARE-AMI) [J].
Assmus, B ;
Schächinger, V ;
Teupe, C ;
Britten, M ;
Lehmann, R ;
Döbert, N ;
Grünwald, F ;
Aicher, A ;
Urbich, C ;
Martin, H ;
Hoelzer, D ;
Dimmeler, S ;
Zeiher, AM .
CIRCULATION, 2002, 106 (24) :3009-3017
[6]   Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium - Feasibility, cell migration, and body distribution [J].
Barbash, IM ;
Chouraqui, P ;
Baron, J ;
Feinberg, MS ;
Etzion, S ;
Tessone, A ;
Miller, L ;
Guetta, E ;
Zipori, D ;
Kedes, LH ;
Kloner, RA ;
Leor, J .
CIRCULATION, 2003, 108 (07) :863-868
[7]   Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].
Bartholomew, A ;
Sturgeon, C ;
Siatskas, M ;
Ferrer, K ;
McIntosh, K ;
Patil, S ;
Hardy, W ;
Devine, S ;
Ucker, D ;
Deans, R ;
Moseley, A ;
Hoffman, R .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48
[8]  
BAUER SR, 2002, POTENTIAL USE TISSUE
[9]  
BERG P, 2004, ASILOMAR RECOMBINANT
[10]  
BOHME G, 2004, GRUNDLAGEN KULTURWIS